If you have long COVID brain fog, you have probably had some version of this conversation: you describe losing your words mid-sentence, forgetting why you walked into a room, being unable to summon the motivation to start a task you genuinely want to do — and someone tells you it sounds like stress. Or anxiety. Or that you should sleep more.
In July 2026, a research team published brain scans that give that experience something it has been missing for four years: a visible, measurable, physical correlate.
I want to walk you through what the study found, because it is genuinely important — and I also want to be careful with you about what it does not yet tell us. Those are both part of an honest answer.
Brain fog after COVID is not a vague complaint
“Brain fog” is an unfortunate term. It sounds soft. It sounds like a mood.
What patients actually describe is specific and consistent: difficulty holding several pieces of information at once, slowed processing, word-finding trouble, and — the symptom people are most reluctant to name out loud — a flattening of drive. Not sadness. Not depression exactly. Just the absence of the internal push that normally gets you from intention to action.
That last one matters, because it is the symptom most often misread as a character problem. Patients tell me they have been called lazy, or unmotivated, by people who love them. Some have started to believe it.
The new imaging data speaks directly to that symptom.
What the 2026 PET study found
The study — “Loss of vesicular monoamine transporter 2 in striatum of long COVID and relationship to neuropsychiatric symptoms” — was published in eBioMedicine, part of the Lancet Discovery Science portfolio, on July 30, 2026. It came out of the University of Toronto and the Centre for Addiction and Mental Health, led by Dr. Jeffrey Meyer with first author Yuhan Karida Liu.
Here is the design, in plain terms.
The researchers used PET imaging — positron emission tomography — with a radioactive tracer that binds to a protein called VMAT2 (vesicular monoamine transporter 2). VMAT2 sits on the nerve terminals of dopamine-producing neurons. It is the machinery that packages dopamine into vesicles so the cell can release it. Because VMAT2 is concentrated at those terminals, measuring how much tracer binds gives you a reasonable proxy for how much intact dopamine terminal you have left.
They scanned 24 adults with long COVID who had significant neuropsychiatric symptoms, and compared them to 24 matched healthy controls.
The long COVID group showed reduced VMAT2 binding across three regions of the striatum — a deep brain structure central to motivation, movement, and learning. The reductions ran roughly 16 to 20 percent depending on the region, averaging about an 18 percent difference in dopamine terminal markers compared with controls.
The part that makes this compelling
The finding that elevates this above “an interesting difference” is that the regional pattern tracked the symptom pattern:
| Striatum region | Its normal role | Symptom it correlated with |
|---|---|---|
| Ventral striatum | Motivation and reward | Apathy — loss of drive |
| Dorsal putamen | Motor control | Physical and motor slowing |
| Dorsal caudate | Executive function, learning | Memory and cognitive difficulty |
That is not a scattered result. The region that handles motivation was the one linked to loss of motivation. The region that handles movement was linked to slowing. This kind of anatomical specificity is what makes researchers take a small study seriously.
Why this matters if you have been dismissed
For four years, one of the hardest parts of long COVID has been the credibility gap. Standard bloodwork often comes back unremarkable. Standard brain MRI often looks normal. And when the tests are normal, patients get told — sometimes gently, sometimes not — that the problem is psychological.
This study used a scan sensitive enough to see something a routine MRI cannot. The difference was there. It was measurable. And it lined up with what patients have been reporting all along.
If you have been carrying the private suspicion that you are imagining this, or that you have simply become a less capable person: this data does not support that interpretation.
What this study does not prove
I would be doing you a disservice if I stopped at the encouraging part. There are four real limitations, and the authors name them themselves.
1. The sample is small. Twenty-four people per group is enough to detect a signal. It is not enough to describe how common this is, or how much it varies from person to person. This needs replication in larger groups.
2. Participants were selected for having neuropsychiatric symptoms. Everyone in the long COVID group already had significant cognitive and motivational complaints. So this does not tell us what the brains of people with primarily respiratory or cardiovascular long COVID look like — they may be entirely different.
3. It shows association, not causation. The scans were taken at one point in time. We cannot tell from this design whether COVID caused the dopamine terminal loss, whether some people had lower baseline levels that made them vulnerable, or whether something downstream of the infection is responsible.
4. Reduced VMAT2 does not necessarily mean dead neurons. This is the most important caveat, and it is the one most likely to get lost in headlines. The study measured protein density, not cell death. Lower VMAT2 signal could reflect neurons that have died — or neurons that are alive but functioning at reduced capacity, or temporarily downregulated. Those possibilities have very different implications, and this study cannot distinguish between them.
We also do not know whether the changes are permanent. Nobody has followed these patients over time yet. Commentary published alongside the study emphasized that longitudinal research is the necessary next step.
So: a real finding, an important finding, and an early one.
What comes next for long COVID brain fog treatment
I want to be direct about something, because there will be a lot of noise about this study in the coming months.
A dopamine finding is not a dopamine prescription. Some coverage has already begun speculating about repurposing existing dopamine-targeting medications. That speculation is premature. No trial has tested whether any such approach improves long COVID cognitive symptoms, and a mechanism that looks tidy on a scan does not reliably translate into a treatment that helps people. Medicine is full of examples where it did not.
If someone offers you a protocol on the basis of this study and tells you it will restore your dopamine system, they are ahead of the evidence. Be careful with them.
What this study genuinely changes is the framing. It supports treating post-COVID cognitive symptoms as a physiological problem deserving a real workup — rather than as a stress reaction to be managed with reassurance. That is a meaningful shift, and it is the one I would encourage you to take from it.
How we approach long COVID at Venturis
At Venturis Clinic in Oklahoma City, long COVID is one of the conditions we evaluate regularly. Patients typically arrive after conventional workups have come back unremarkable and they have been told there is nothing further to investigate.
Our approach starts where it should start: with a thorough history and an individualized evaluation, because post-COVID presentations differ enormously from person to person. Fatigue-dominant, cognitive-dominant, autonomic, and inflammatory-dominant presentations are not the same problem and should not receive the same workup.
We are a direct-pay practice and do not bill insurance. We are upfront about that in the first conversation rather than after an evaluation is underway, because it is a real tradeoff and you deserve to weigh it with full information. What that allows is an evaluation built around what you actually need rather than what a carrier will authorize.
I do not know whether we can help you until I have evaluated you. You should be cautious with anyone who claims otherwise before meeting you — including me.
Learn more about long COVID evaluation at our Oklahoma City clinic →
Frequently asked questions
Is long COVID brain fog real, or is it psychological?
The July 2026 eBioMedicine PET study found measurable reductions in dopamine nerve terminal markers in the striatum of people with long COVID and neuropsychiatric symptoms, compared with healthy controls. The regional pattern of those reductions corresponded to the specific symptoms participants reported. This is physiological evidence, though as an early study with 24 participants per group it requires replication.
How long does brain fog after COVID last?
This varies substantially between individuals and there is no reliable way to predict an individual course. The 2026 imaging study was a single-timepoint study and did not follow participants over time, so it cannot tell us whether the changes it observed persist, improve, or resolve. Longitudinal research is still needed.
Does this study mean dopamine medication will help long COVID brain fog?
No. The study identified an association between reduced dopamine terminal markers and symptoms. It did not test any treatment. No clinical trial has established that dopamine-targeting medication improves long COVID cognitive symptoms, and any claim otherwise is currently ahead of the evidence.
What kind of doctor should I see for long COVID brain fog?
Start with a clinician willing to take a full history and investigate rather than attribute the symptoms to stress by default. Post-COVID presentations vary widely, so an individualized evaluation matters more than a standardized protocol.
Do you see long COVID patients in Oklahoma City?
Yes. Venturis Clinic is located at 7917 N May Ave, Suite B, Oklahoma City, OK 73120. You can reach the office at (405) 848-7246 to ask about scheduling an evaluation.
Dr. Alvin Philipose, B.S., B.S., DC, ICCP, practices at Venturis Clinic in Oklahoma City, Oklahoma.
Medical disclaimer: This article is for general educational purposes and does not constitute medical advice, diagnosis, or treatment, and does not establish a doctor–patient relationship. Research described here is early and its clinical implications are not established. Individual results vary. Always consult a qualified healthcare provider about your own symptoms. These statements have not been evaluated by the Food and Drug Administration.
Sources
- Liu YK, Meyer JH, et al. “Loss of vesicular monoamine transporter 2 in striatum of long COVID and relationship to neuropsychiatric symptoms.” eBioMedicine, 30 July 2026. DOI: 10.1016/j.ebiom.2026.106339
- “Dopaminergic vulnerability in long COVID: striatal PET imaging at the brain-body interface.” eBioMedicine commentary, 2026.
- CIDRAP, University of Minnesota — “New study offers clues about long COVID’s brain symptoms,” 2026.